KMKamel Mohammedi

Kamel Mohammedi

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kamel Mohammedi has a total of 221 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic Insights Into Protective Effects of GLP-1 Receptor Agonists on Stroke and Alzheimer Disease Across Ancestries

    by Ilana Caro-Châtelier, Muralidharan Sargurupremraj, Chengran Yang, Callistus Akinleye, David-Alexandre Trégouët, Rufus Olusola Akinyemi, Daichi Shigemizu, Motunrayo Coker, Joshua O. Akinyemi, Hemant K. Tiwari, et al.

    Background and ObjectivesStroke and dementia are leading causes of death and disability worldwide, requiring enhanced preventive strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RA), wid...

  • Open Access

    Long term neuropsychological evaluation of adult patients with craniopharyngiomas

    by Julie Guillotin, Charlotte Planchon, Julien Engelhardt, Edouard Gimbert, Thomas Cuny, Fadi Alkhiami, Kamel Mohammedi, Antoine Tabarin, Blandine Gatta Cherifi

    Introduction Craniopharyngiomas are benign tumors that develop in the hypothalamic-pituitary region. Their treatment mainly involves surgery, sometimes combined with radiotherapy. The hypothalamus plays an essential role in hormonal balance and energy regulation, but also in cognition through connectivity circuits. The cognitive impact of craniopharyngioma treatment is poorly understood and has mainly been studied in children. Patients and methods We report the neuropsychological assessments of 22 adult patients treated for craniopharyngioma with a follow-up of at least 5 years, 16 of whom were diagnosed while being adults. All assessments were performed by a neuropsychologist using validated tests. More than 65% of patients, including those diagnosed in adulthood, showed at least one impairment in executive functioning, especially cognitive inhibition or deficit in organization. 75% of patients reported fatigue. For half of these patients, these impairments needed specific treatment like cognitive rehabilitation. Conclusion Neuropsychological evaluation has to be part of the follow-up of patients treated for a craniopharyngioma including those diagnosed during adulthood.

  • Determination of pentosidine in fingernails by liquid chromatography with fluorescence detection (LC-FL) – Methodology and association with glycated hemoglobin (HbA1c), skin autofluorescence (SAF) and other ungual glycation biomarkers among people with diabetes.

    by Dinh Hieu Nguyen, Michael Howsam, Karina Ille, Laetitia Normandin, Kamel Mohammedi, Cécile Delcourt, Catherine Helmer, Mélanie Le Goff, Eric Boulanger, Vincent Rigalleau, et al.

  • Open Access

    A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline

    by Hertzel C. Gerstein, Zayeeda Labiba, Sibylle Hess, Kamel Mohammedi, Yueci Zhou, Shun Fu Lee

    Objective: The importance of randomised trials for discerning an intervention's effect rests on randomisation's ability to create groups with (on average) equal hazards of future outcomes. The frequency with which this does not occur in well‐designed large trials with a high event rate was studied. Research Design and Methods: Data from 8215 participants in the Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) trial's biomarker study were used to simulate multiple trials. Participants were repeatedly randomised to two groups. After each randomisation, the hazard of death in people assigned to one versus the other was calculated. A set of 1000 randomisations was repeated 1000 times, and the number of pairs for which the hazard ratio was < 0.85 or > 1.18 was tabulated within each set of 1000. Whether such imbalances in hazard could be detected or mitigated by adjusting for baseline covariates was explored using adjusted Cox models. Results: In a median of 3 (IQR 2, 4) of 1000 randomisations (0.3%) the hazard ratio for death of assignment to one group versus the other was < 0.85 or > 1.18 by chance alone. This imbalance was not apparent from baseline data and could not be fully mitigated by adjustment for baseline independent predictors of death using data from four randomisations that yielded imbalanced hazards. Conclusion: One out of every 300–400 large, two‐arm outcomes trials have imbalances in the baseline hazard of the primary outcome that are large enough to misrepresent the true effect of the intervention.

  • Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes

    by Julian W. Sacre, Kristin Lundegard, Kamel Mohammedi, Bendix Carstensen, Hertzel C. Gerstein, Jonathan E. Shaw

    Aims: Heart failure (HF) may develop in type 2 diabetes without prior cardiovascular disease (CVD). This study aimed to identify risk factors that distinguish CVD that presents first as a HF event versus CVD that presents first as an atherosclerotic event (ASCVD), among people with type 2 diabetes. Materials and methods: ORIGIN and REWIND trial participants with type 2 diabetes but free of CVD ( N = 6175; 64 ± 7 years, 50.1% female) were followed for ~5.8 years for incident CVD presenting first as either a HF event (HF hospitalization or HF death), ASCVD (myocardial infarction, unstable angina, stroke, or revascularization), or other cardiovascular death. Multi‐state models characterised event‐specific associations of risk factors with each possible first CVD event. Results: HF was the first event in 16.8% of 1024 incident CVD cases. Older age, higher BMI, and higher urine albumin:creatinine ratio were more strongly associated with CVD manifesting first as HF, rather than as ASCVD or other cardiovascular death. ASCVD as the first event (65.2% of cases) was more strongly associated with worse LDL‐cholesterol and HbA1c. These unique associations of risk factors with HF versus ASCVD translated to variable probabilities of HF as the first CVD event, depending on the clinical profile (32.0% for a profile enriched with HF‐specific risk factors versus 5.1% for a profile enriched with ASCVD‐specific risk factors). Conclusions: CVD that presents first as a HF event is common in type 2 diabetes and its risk factors are distinct from those associated with CVD that presents first as an ASCVD event.


  • Body-weight Cycling and Risk of Diabetic Kidney Disease in People With Type 1 Diabetes in the DCCT/EDIC Population

    by Marion Camoin, Kamel Mohammedi, Pierre-Jean Saulnier, Samy Hadjadj, Jean-François Gautier, Jean-Pierre Riveline, Nicolas Venteclef, Louis Potier, Gilberto Velho

    Context: Intraindividual body-weight variability or cycling is associated with increased risk of chronic kidney disease (CKD) in the general population. Objective: We conducted a retrospective analysis of data from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) studies to assess association between body-weight cycling and the risk of renal events in type 1 diabetes. Methods: Four indices of intraindividual body-weight variability were calculated for 1432 participants of DCCT/EDIC taking into account body-weight measurements during the DCCT follow-up (6 ± 2 years). Variability independent of the mean (VIM) was the main index. Six criteria of progression to CKD were studied during DCCT/EDIC follow-up (21 ± 4 years). Hazard ratio (HR) with 95% confidence interval (CI) were computed in Cox analyses for 1 SD of the indices expressed as Z-score. Results: A high VIM was significantly associated with the incidence of a 40% decline in eGFR from baseline values (HR, 1.25; 95% CI, 1.09-1.41; P = .001), doubling of baseline serum creatinine (HR, 1.34; 95% CI, 1.13-1.57; P = .001), CKD stage 3 (HR, 1.36; 95% CI, 1.12-1.63; P = .002), and with a decline in eGFR > 3 mL/min/m2 per year (all analyses adjusted for CKD risk factors at baseline and follow-up, and use of nephroprotective drugs). VIM was also associated with the incidence of moderately and severely increased albuminuria, but associations did not remain significant following adjustment for follow-up covariates. Similar results were observed for the other indices of body-weight cycling. Conclusion: Body-weight cycling is significantly associated with an increased risk of kidney events in people with type 1 diabetes, regardless of body mass index and traditional risk factors.


  • Open Access

    Genetic predisposition to nephropathy and associated cardiovascular disease in people with type 1 diabetes: role of the angiotensinI-converting enzyme (ACE), and beyond; a narrative review

    by Kamel Mohammedi, Michel Marre, François Alhenc-Gelas

    Hypertension, cardiovascular disease and kidney failure are associated with persistent hyperglycaemia and the subsequent development of nephropathy in people with diabetes. Diabetic nephropathy is associated with widespread vascular disease affecting both the kidney and the heart from an early stage. However, the risk of diabetic nephropathy in people with type 1 diabetes is strongly genetically determined, as documented in familial transmission studies. The search for the underlying genes has been extensive, using specific hypotheses, sibling linkage studies and genome-wide association studies (GWAS). The role of the angiotensinI-converting enzyme/kininase II (ACE) gene and genetic variability in ACE levels as a susceptibility and prognostic factor for diabetic nephropathy has been well documented in people with type 1 diabetes. The ACE gene insertion/deletion polymorphism, which is associated with plasma and tissue ACE levels, has been the most studied genomic variant in diabetic nephropathy. Recently, this polymorphism has also been associated with longevity in people with type 1 diabetes. The ACE I/D polymorphism has also been associated with vascular, extra-renal complications including myocardial infarction and lower-limb amputation in this population. Other genes and loci have been identified in linkage studies and GWAS, such as the COL4A3 gene or a region on chromosome 3q with the adiponectin gene. Replication was not always attempted and was rarely achieved, even for GWAS. Overall, effect sizes remain modest and no major gene has been identified, despite the strength of the genetic effect in transmission studies. We searched bibliographic databases for studies reporting genomic variants associated with diabetic nephropathy and meta-analyses of such studies. We selected important relevant studies for further discussion in this narrative review. This brief review attempts to summarise the current knowledge on the genetics of diabetic nephropathy and associated cardiovascular disease in people with type 1 diabetes, and discusses some conceptual and methodological issues relevant to the interpretation of past studies and the design of future ones.


  • Determination of glycation biomarkers in human fingernails by isotope-dilution liquid chromatography tandem mass spectrometry (LC-MS/MS)

    by Frédéric J. Tessier, Sarahi Jaramillo Ortiz, Dinh Hieu Nguyen, Kamel Mohammedi, Cécile Delcourt, Catherine Helmer, Mélanie Le Goff, Eric Boulanger, Vincent Rigalleau, Michael Howsam


  • Open Access

    Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: “INSIST” study

    by Kamel Mohammedi, Laurent Fauchier, Nadia Quignot, Artak Khachatryan, Tamar Banon, Raissa Kapnang, Kazue Kikuchi, Hongye Ren, Christine Massien, Lucile Vigié, et al.

    Background: People with type 2 diabetes (T2D) are at elevated risk of cardiovascular disease (CVD) including stroke, yet existing real-world evidence (RWE) on the clinical and economic burden of stroke in this population is limited. The aim of this cohort study was to evaluate the clinical and economic burden of stroke among people with T2D in France. Methods: We conducted a retrospective RWE study using data from the nationally representative subset of the French Système National des Données de Santé (SNDS) database. We assessed the incidence of stroke requiring hospitalization between 2012 and 2018 among T2D patients. Subsequent clinical outcomes including CVD, stroke recurrence, and mortality were estimated overall and according to stroke subtype (ischemic versus hemorrhagic). We also examined the treatment patterns for glucose-lowering agents and CVD agents, health care resource utilization and medical costs. Results: Among 45,331 people with T2D without baseline history of stroke, 2090 (4.6%) had an incident stroke requiring hospitalization. The incidence of ischemic stroke per 1000 person-years was 4.9-times higher than hemorrhagic stroke (6.80 [95% confidence interval (CI) 6.47–7.15] versus 1.38 [1.24–1.54]). During a median follow-up of 2.4 years (interquartile range 0.6; 4.4) from date of index stroke, the rate of CVD, stroke recurrence and mortality per 1000 person-years was higher among hemorrhagic stroke patients than ischemic stroke patients (CVD 130.9 [107.7–159.0] versus 126.4 [117.2–136.4]; stroke recurrence: 86.7 [66.4–113.4] versus 66.5 [59.2–74.6]; mortality 291.5 [259.1–327.9] versus 144.1 [134.3–154.6]). These differences were not statistically significant, except for mortality (adjusted hazard ratio 1.95 [95% CI 1.66–2.92]). The proportion of patients prescribed glucagon-like peptide-1 receptor agonists increased from 4.2% at baseline to 6.6% during follow-up. The proportion of patients prescribed antihypertensives and statins only increased slightly following incident stroke (antihypertensives: 70.9% pre-stroke versus 76.7% post-stroke; statins: 24.1% pre-stroke versus 30.0% post-stroke). Overall, 68.8% of patients had a subsequent hospitalization. Median total medical costs were €12,199 (6846; 22,378). Conclusions: The high burden of stroke among people with T2D, along with the low proportion of patients receiving recommended treatments as per clinical guidelines, necessitates a strengthened and multidisciplinary approach to the CVD prevention and management in people with T2D.